Inzucchi, S. E., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Verma, S., Han, Y., Kerr Saraiva, J. F., Bengtsson, O., Petersson, M., Langkilde, A. M., McMurray, J. J. V., & Solomon, S. D. (2022). efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet, 10(12), 869–881. http://access.bl.uk/ark:/81055/vdc_100170103596.0x000007